



Barbara Ann Burrall, M.D.

Philosophy of Care

Dr. Burrall finds dermatology very interesting - and fun - because it combines the study of many diverse fields of medicine. With dermatologic disease, treatment decisions are often influenced by the patient's feelings about the disease, so she tries to include her patients actively in the decision-making process and the treatment plan. Good dermatological health requires avoidance of excessive sun exposure. Using good sun protection also proves extremely beneficial. Overall good patient care necessitates cooperation among different specialists and the primary care doctor, a good working relationship that focuses on the patient. Dr. Burrall has been associated with UC Davis since 1981, and enjoys collaborating with physicians from many other specialties to provide outstanding care for her patients.

Clinical Interests

Dr. Burrall finds dermatology very interesting ? and fun ? because it combines the study of many diverse fields of medicine. Since treatment decisions about dermatologic disease are often influenced by the patient's feelings about the disease, she tries to include her patients actively in the decision-making process and the treatment plan. She offers computer-imaging body mapping of moles to track changes.

Title Health Sciences Clinical Professor

Clinical Medical Director

Editor in Chief, Dermatology Online Journal

Specialty

Medical Dermatology, Phototherapy, Skin Cancer

Department

[Dermatology](#)

Division

Dermatology

Clinic

UC Davis Medical Group, Sacramento - Midtown

Center/Program Affiliation

[UC Davis Comprehensive Cancer Center](#)

Address/Phone

Cannery Building, Dermatology, 3301 C St. Suite 1300-1400 Sacramento, CA 95816

Phone: 916-734-6111

UC Davis Midtown Ambulatory Care Center, UC Davis Medical Group - Midtown Family Medicine, 3160 Folsom Blvd Suite 1400 Sacramento, CA 95816

Phone: 916-734-5846

Additional Phone



Barbara Ann Burrall, M.D.

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education M.D., UC Irvine College of Medicine, Irvine CA 1980
B.S., UCLA, Los Angeles CA 1976

Internships San Joaquin General Hospital, Stockton CA 1980-1981

Residency Dermatology, UC Davis Medical Center, Sacramento CA 1981-1984

Board Certifications American Board of Dermatology, 1985

Professional Memberships American Academy of Dermatology - Fellow
American Board of Dermatology

Honors and Awards Physician Scientist Award-National Institute of Allergy and Infectious Disease, NIH, 1985
Bank of America-Giannini Foundation Medical Fellow, 1983
Medical Scholar Award, University of California, Davis, 1982
Departmental Honors, Biochemistry, University of California, Los Angeles, 1976
Magna Cum Laude, Biochemistry, University of California, Los Angeles, 1976

Select Recent Publications Lim YH, Qiu J, Saraceni C, Burrall BA, Choate KA. Genetic Reversion via Mitotic Recombination in Ichthyosis with Confetti due to a KRT10 Polyalanine Frameshift Mutation. *J Invest Dermatol.* 2016 Aug;136(8):1725-8.

Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. *J Am Acad Dermatol.* 2015 Oct;73(4):645-54.

Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F. Metastatic melanoma - a review of current and future treatment options. *Acta Derm Venereol.* 2015 May;95(5):516-24.

Patel F, Wilken R, Burrall B, Martinez S, Wells V, King B, Maverakis E. Detailed protocol for



Barbara Ann Burrall, M.D.

administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines. *Dermatol Online J.* 2014 Nov 15;20(11).

Sharon V, Burrall B, Patel F, He Y, Konia T, Villalobos IB, Maverakis E. Multimodal therapy of idiopathic pyoderma gangrenosum. *Dermatol Online J.* 2014 Jun 15;20(6).

© 2018 UC Regents